With the public health emergency soon coming to an end, people covered by Medicaid will encounter new barriers, discusses Dennis Scanlon, PhD, professor of health policy and administration, Penn State University.
The end of the COVID-19 pandemic comes with new hurdles and fear of coverage gaps for states and individuals who are currently covered by Medicaid, says Dennis Scanlon, PhD, professor of health policy and administration, Penn State University.
Transcript
The US has had continuous Medicaid coverage for 3 years because of the pandemic, and that provision is now ending. What can states do to ensure that coverage gains are maintained with minimal disruption?
This really relates to the COVID-19 pandemic and the emergency authorization—basically, a public health emergency—to allow Medicaid beneficiaries to maintain their coverage and not have to go through re-enrollment or be kicked off of Medicaid coverage during that public health emergency. With that ending, it's going to require states to make decisions. I think we'll see variation across states and for beneficiaries on Medicaid, in terms of how this all plays out.
In some sense, it's part of, I guess you could call it maybe a natural experiment or a political experiment. A couple thoughts: One is, individuals maintaining health insurance coverage generally has shown to be beneficial for their health. A key question will be, of those who had maintained their coverage, how many are still eligible vs are no longer eligible because they don't meet the Medicaid coverage criteria? And there's variation in that and what it is. I would expect to see state-by-state variation.
If not covered by Medicaid, the question is, what other options does one have? Well, one has the Affordable Care Act exchanges, the ACA exchanges, with the subsidies that are available from the federal government, and then, of course, employment-based insurance or Medicare coverage as well. It's not that everyone that might no longer be eligible for Medicaid has no option, but the question is, do they take up that option? Can they afford that option? How do they get access and know about those options?
I think a lot of education is going to have to happen, but even on the re-enrollment side. How are states going to process and notify people that you may still be eligible, but you have to qualify, you have to re-enroll. For some of these individuals that first were covered by Medicaid and then the pandemic hit, this may be the first time that they go through that re-enrollment process. So, a lot of this is going to be really procedural and depend on how the different states [proceed], because we have, essentially, each state has its own Medicaid program, although it's jointly funded by the federal government. And of course, we know that Medicaid expansion was taken up by many, but not all states, as a result of the Affordable Care Act.
So, we will see some variation, but I think the key thing will be, are there gaps in coverage? What impact does that have on health, and ultimately, how much of the variation that might naturally occur from certain states to other states may allow us to understand the importance of insurance coverage, is kind of part of this experiment.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More